Archives — January 2014 back to current month (9)

Two Companies Follow Unmet Needs to Biotech Profits: Echo He (01/30/2014)

Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients often run out of alternatives immediately after they are diagnosed. In this interview with The Life Sciences Report, Echo He of the Maxim Group discusses her focus on how patients with unmet needs might ultimately get a fighting chance. To that end, she has selected two names that could produce both welcome cures and stunning share price results for investors who understand the value proposition of last-resort therapies.

more>

The Year of RNA? (01/28/2014)

So 2013 was a huge year for RNA, but could 2014 be even bigger?

more>

The Last Word: Place Your Biotech Bets on Solid Management and Hot Therapy Areas (01/23/2014)

pillbill82Who got the last word at the 2014 Biotech Showcase? A portfolio manager specializing in healthcare, an award-winning analyst, and a pair of venture capitalists with global viewpoints and a focus on clinical-stage companies. In the closing event of the showcase, cohosted by The Life Sciences Report, this panel of experts offered insights into trends that will influence the biotech universe in 2014.

more>

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (01/15/2014)

stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.

more>

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (01/15/2014)

stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report.

more>

Biotech Showcase Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (01/15/2014)

stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.

more>

Sorting Through the Chaff: The Michael J. Fox Foundation's Tracey Mumford on the Quest to Cure Parkinson's Disease (01/09/2014)

The business of drug development survives by saving lives, but sometimes nonprofit, private activism is needed to kick-start a new medicine into development. The Michael J. Fox Foundation for Parkinson's Research is the world's largest nonprofit funder of Parkinson's disease research, having awarded more than $400 million in grants during its 13-year existence. Senior Associate Director of Research Partnerships Tracey Mumford is the foundation's link to companies with good ideas. In this interview with The Life Sciences Report, Mumford discusses exciting companies that have warranted foundation supportócompanies that investors might find very interesting.

more>

The Biological iPhone (01/03/2014)

"The next Steve Jobs might be tinkering with DNA molecules instead of circuit boards."

more>

Follow the M&A Money to Small- and Mid-Cap Cardiovascular Medtechs: Jason Mills (01/02/2014)

Some investors' eyes glaze over at the mention of medical devices. But it's time to wake up and focus on the stunning growth opportunities in small- and mid-cap cardiovascular medtech. Canaccord Genuity Managing Director Jason Mills covers companies on the front lines of innovation and in sectors where the trifecta of revenue, margins and reimbursement is achieving biotechlike levels. In this interview with The Life Sciences Report, Mills opens the new year with a discussion of the cardiovascular medtech industry and mentions companies that are probable acquisition candidates.

more>

More Archives

2017Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec